Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
136
datasets available to search
ShareScore release 0.9.0
Dataset results
136 results for “quercetin”
Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19
ClinicalTrials.gov study NCT04861298. IPD Sharing: NO. Countries: 1. Publications: 1.
Effect of Quercetin Supplementation on Endometriosis Outcomes
ClinicalTrials.gov study NCT05983224. IPD Sharing: YES. Countries: 1. Publications: 2.
Safety and Effectivness of Quercetin & Dasatinib on Epigenetic Aging
ClinicalTrials.gov study NCT04946383. IPD Sharing: NO. Countries: 1. Publications: 3.
Quercetin's Effect on Bone Health and Inflammatory Markers
ClinicalTrials.gov study NCT05371340. IPD Sharing: NO. Countries: 1. Publications: 1.
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
ClinicalTrials.gov study NCT05838560. IPD Sharing: YES. Countries: 1. Publications: 1.
Effects of Quercetin on Metabolic Health
ClinicalTrials.gov study NCT05297032. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
The Effect of Quercetin in Sarcoidosis
ClinicalTrials.gov study NCT00402623. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Oral Curcumin, Quercetin and Vitamin D3 Supplements for Mild to Moderate Symptoms of COVID-19
ClinicalTrials.gov study NCT04603690. IPD Sharing: NO. Countries: 1. Publications: 1.
Biological Effects of Quercetin in COPD
ClinicalTrials.gov study NCT03989271. IPD Sharing: NO. Countries: 1. Publications: 5.
Nutritional Supplementation of Flavonoids Quercetin and Curcumin for Early Mild Symptoms of COVID-19
ClinicalTrials.gov study NCT05130671. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Biological Effects of Quercetin in COPD Phase II
ClinicalTrials.gov study NCT06003270. IPD Sharing: NO. Countries: 1. Publications: 4.
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
ClinicalTrials.gov study NCT05724329. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Fungicide suppression of flight performance in the honey bee (Apis mellifera) and its amelioration by quercetin
Open the record for dataset details and reuse information.
Data from: Anthracycline drugs on modified surface of quercetin-loaded polymer nanoparticles: a dual drug delivery model for cancer treatment
Polymer nanoparticles are vehicles used for delivery of hydrophobic anti-cancer drugs, like doxorubicin, paclitaxel or chemopreventors like quercetin (Q). The present study deals with the synthesis and characterisation of nano formulations (NFs) from Q loaded PLGA (poly lactic-co-glycolic acid) nano particles (NPs) by surface modification. The surface of Q-loaded (NPs) is modified by coating with biopolymers like bovine serum albumin (BSA) or histones (His). Conventional chemotherapeutic drugs adriamycin (ADR) and mitoxantrone (MTX) are bound to BSA and His respectively before being coated on Q-loaded NPs to nano formulate NF1 and NF2 respectively. The sizes of these NFs are in the range 400-500 nm as ascertained by SEM and DLS measurements. Encapsulation of Q in polymer NPs is confirmed from shifts in FT-IR, TGA and DSC traces of Q-loaded NPs compared to native PLGA and Q. Surface modification in NFs is evidenced by three distinct regions in their TEM images; the core, polymer capsule and the coated surface. Negative zeta potential of Q-loaded NPs shifted to positive potential on surface modification in NF1 and NF2. In vitro release of Q from the NFs lasted up to twenty days with an early burst release. NF2 is better formulation than NF1 as loading of MTX is 85% compared to 23% loading of ADR. Such NFs are expected to overcome multi-drug resistance (MDR) by reaching and treating the target cancerous cells by virtue of size, charge and retention.
Figure 6 from: Demkovych A, Bondarenko Y, Shcherba V, Luchynskyi V, Vitkovskyy V, Machogan V (2021) Quercetin effects on adaptive immune response in experimental periodontitis of bacterial-immune genesis. Pharmacia 68(4): 877-882. https://doi.org/10.3897/pharmacia.68.e70883
Figure 6 Dynamics of the natural killers content in the rat's blood on the 14th day of the research in conditions of experimental bacterial-immune periodontitis development and treatment by quercetin (% of control). Notes. * – significant of differences in relation to the intact animals (p<0.01); ● – significant of differences in relation to the intact animals (p<0.05); # – significant of differences in relation to the animals with periodontitis on the 14th day of the experiment without treatment (p<0.01).
Figure 1 from: Demkovych A, Bondarenko Y, Shcherba V, Luchynskyi V, Vitkovskyy V, Machogan V (2021) Quercetin effects on adaptive immune response in experimental periodontitis of bacterial-immune genesis. Pharmacia 68(4): 877-882. https://doi.org/10.3897/pharmacia.68.e70883
Figure 1 Dynamics of the content of common mature T-lymphocytes in the rat's blood on the 14th day of the research in conditions of experimental bacterial-immune periodontitis development and treatment by quercetin (% of control). Notes: * – significant of differences in relation to the intact animals (p<0.01); # – significant of differences in relation to the animals with periodontitis on the 14th day of the experiment without treatment (p<0.01).
Figure 5 from: Demkovych A, Bondarenko Y, Shcherba V, Luchynskyi V, Vitkovskyy V, Machogan V (2021) Quercetin effects on adaptive immune response in experimental periodontitis of bacterial-immune genesis. Pharmacia 68(4): 877-882. https://doi.org/10.3897/pharmacia.68.e70883
Figure 5 Dynamics of the common B-lymphocytes content in the rat's blood on the 14th day of the research in conditions of experimental bacterial-immune periodontitis and treatment by quercetin (% of control). Notes. * – significant of differences in relation to the intact animals (p<0.01); ● – significant of differences in relation to the intact animals (p<0.05); # – significant of differences in relation to the animals with periodontitis on the 14th day of the experiment without treatment (p<0.01).
Figure 2 from: Demkovych A, Bondarenko Y, Shcherba V, Luchynskyi V, Vitkovskyy V, Machogan V (2021) Quercetin effects on adaptive immune response in experimental periodontitis of bacterial-immune genesis. Pharmacia 68(4): 877-882. https://doi.org/10.3897/pharmacia.68.e70883
Figure 2 Dynamics of the content of T-helpers in the rat's blood on the 14th day of the research in conditions of experimental bacterial-immune periodontitis development and treatment by quercetin (% of control). Notes. * – significant of differences in relation to the intact animals (p<0.01); ● – significant of differences in relation to the intact animals (p<0.05); # – significant of differences in relation to the animals with periodontitis on the 14th day of the experiment without treatment (p<0.01).
Figure 4 from: Demkovych A, Bondarenko Y, Shcherba V, Luchynskyi V, Vitkovskyy V, Machogan V (2021) Quercetin effects on adaptive immune response in experimental periodontitis of bacterial-immune genesis. Pharmacia 68(4): 877-882. https://doi.org/10.3897/pharmacia.68.e70883
Figure 4 Dynamics of immunoregulatory index on the 14th day of the research in conditions of experimental bacterial-immune periodontitis development and treatment by quercetin (% of control). Notes. * – significant of differences in relation to the intact animals (p<0.01); # – significant of differences in relation to the animals with periodontitis on the 14th day of the experiment without treatment (p<0.01).
Figure 3 from: Demkovych A, Bondarenko Y, Shcherba V, Luchynskyi V, Vitkovskyy V, Machogan V (2021) Quercetin effects on adaptive immune response in experimental periodontitis of bacterial-immune genesis. Pharmacia 68(4): 877-882. https://doi.org/10.3897/pharmacia.68.e70883
Figure 3 Dynamics of the content of T-effectors in the rat's blood on the 14th day of the research in conditions of experimental bacterial-immune periodontitis development and treatment by quercetin (% of control). Notes. * – significant of differences in relation to the intact animals (p<0.01); # – significant of differences in relation to the animals with periodontitis on the 14th day of the experiment without treatment (p<0.01).
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.